Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lipocine (LPCN) EPS (Weighted Average and Diluted) (2016 - 2025)

Lipocine (LPCN) has disclosed EPS (Weighted Average and Diluted) for 13 consecutive years, with -$0.59 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EPS (Weighted Average and Diluted) fell 34.09% year-over-year to -$0.59, compared with a TTM value of -$1.79 through Sep 2025, down 132.47%, and an annual FY2024 reading of $0.0, up 100.05% over the prior year.
  • EPS (Weighted Average and Diluted) was -$0.59 for Q3 2025 at Lipocine, down from -$0.41 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $0.66 in Q1 2024 and bottomed at -$1.27 in Q3 2023.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.3, with a median of -$0.41 recorded in 2025.
  • The sharpest move saw EPS (Weighted Average and Diluted) surged 450.0% in 2021, then crashed 4133.33% in 2023.
  • Year by year, EPS (Weighted Average and Diluted) stood at $0.14 in 2021, then crashed by 407.14% to -$0.43 in 2022, then changed by 0.0% to -$0.43 in 2023, then skyrocketed by 177.01% to $0.33 in 2024, then crashed by 278.16% to -$0.59 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for LPCN at -$0.59 in Q3 2025, -$0.41 in Q2 2025, and -$0.35 in Q1 2025.